Conference abstract
Antiretroviral therapy including tenofovir might favour immunity against SARS-COV-2 in people living with HIV followed at Dream Center-Dschang
Pan African Medical Journal - Conference Proceedings. 2023:18(156).03
Oct 2023.
doi: 10.11604/pamj-cp.2023.18.156.2269
Archived on: 03 Oct 2023
Contact the corresponding author
Keywords: cART, COVID-19, HIV, IgG, Dschang, DREAM
Oral presentation
Antiretroviral therapy including tenofovir might favour immunity against SARS-COV-2 in people living with HIV followed at Dream Center-Dschang
Angyiba Serge Andigema1,&, Ngomtcho Sen Claudine Henriette2, Nguila David3, Nfor Nadine Beri1, Nsah Bongdze-Em Lilian1, Katarzynga Chiweleska3, Charles Kouanfack4, Ateudjieu Jérôme4, Simo Gustave5
1Department of Microbiology, Immunology and Hematology; Faculty of medicine and pharmaceutical Sciences, University of Dschang, Cameroon, 2University of Dschang, Dschang, Cameroon, 3Dream Center, Dschang, Dschang, Cameroon, 4Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Cameroon, 5Department of Molecular Biology and Entomology, Faculty of Sciences, University of Dschang, Cameroon
&Corresponding author
Introduction: since its first appearance in Wuhan, severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) has become a pandemic. The protective action of some antiretroviral (ARV) medications against SARS-COV-2 has been reported. Thus we evaluated the immune response of HIV patients under ARV therapy at DREAM Laboratory Dschang. The objective was to evaluate the response of HIV patients under antiretroviral treatment exposed to SARS-CoV-2 followed up at DREAM Center Dschang.
Methods: an analytical prospective and retrospective study was conducted at DREAM Center Dschang. 323 PLWH were recruited by consecutive sampling methods following the ethical requirements. Blood samples were collected; CD4 and viral load were dosed. Additionally, data were collected from registers before, during, and after the epidemic pic. Strata sampling was done and we selected 82 patients based on variations in CD4 count and viral load profile to detect anti-SARS-CoV-2 IgG antibodies using a semi-quantitative ELISA.
Results: the sex ratio was 2.2 in favor of females, and the mean age was 42.03± 2.52 years. The overall seroprevalence of SARS-COV-2 was 50% (41/82) in PLWH. AntiSARS-CoV-2 IgG antibodies were more detected in females (23/41: 56.09%) and in the age group [26-45] years (18/41: 43.9%). Amongst the patients in whom anti-SARS-COV-2 IgG was not detected, 36/41 (90%) had TDF molecule in their therapy and the difference was significant (P<0.036) with those who did not 5/41 (%). Moreover, amongst those who developed antibodies, 27/41 (66%) were on a therapy including TDF.
Conclusion: this study demonstrates that PLWH under TDF might be more protected against SARS-CoV-2. These results give room for future investigations, targeting a larger population of HIV care centers for better monitoring of COVID-19 in PLWH.
Antiretroviral therapy including tenofovir might favour immunity against SARS-COV-2 in people living with HIV followed at Dream Center-Dschang
Angyiba Serge Andigema1,&, Ngomtcho Sen Claudine Henriette2, Nguila David3, Nfor Nadine Beri1, Nsah Bongdze-Em Lilian1, Katarzynga Chiweleska3, Charles Kouanfack4, Ateudjieu Jérôme4, Simo Gustave5
1Department of Microbiology, Immunology and Hematology; Faculty of medicine and pharmaceutical Sciences, University of Dschang, Cameroon, 2University of Dschang, Dschang, Cameroon, 3Dream Center, Dschang, Dschang, Cameroon, 4Department of Public Health, Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Cameroon, 5Department of Molecular Biology and Entomology, Faculty of Sciences, University of Dschang, Cameroon
&Corresponding author
Introduction: since its first appearance in Wuhan, severe acute respiratory syndrome coronavirus 2 (SARSâ€CoVâ€2) has become a pandemic. The protective action of some antiretroviral (ARV) medications against SARS-COV-2 has been reported. Thus we evaluated the immune response of HIV patients under ARV therapy at DREAM Laboratory Dschang. The objective was to evaluate the response of HIV patients under antiretroviral treatment exposed to SARS-CoV-2 followed up at DREAM Center Dschang.
Methods: an analytical prospective and retrospective study was conducted at DREAM Center Dschang. 323 PLWH were recruited by consecutive sampling methods following the ethical requirements. Blood samples were collected; CD4 and viral load were dosed. Additionally, data were collected from registers before, during, and after the epidemic pic. Strata sampling was done and we selected 82 patients based on variations in CD4 count and viral load profile to detect anti-SARS-CoV-2 IgG antibodies using a semi-quantitative ELISA.
Results: the sex ratio was 2.2 in favor of females, and the mean age was 42.03± 2.52 years. The overall seroprevalence of SARS-COV-2 was 50% (41/82) in PLWH. AntiSARS-CoV-2 IgG antibodies were more detected in females (23/41: 56.09%) and in the age group [26-45] years (18/41: 43.9%). Amongst the patients in whom anti-SARS-COV-2 IgG was not detected, 36/41 (90%) had TDF molecule in their therapy and the difference was significant (P<0.036) with those who did not 5/41 (%). Moreover, amongst those who developed antibodies, 27/41 (66%) were on a therapy including TDF.
Conclusion: this study demonstrates that PLWH under TDF might be more protected against SARS-CoV-2. These results give room for future investigations, targeting a larger population of HIV care centers for better monitoring of COVID-19 in PLWH.
